Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.64 | N/A | +5.09% |
management commentary, guidance changes, and full analysis available with Pro.
| +5.09% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting the company's commitment to its product pipeline. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value through our pipeline.
Bristol Myers Squibb's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 1.55%. This drop may reflect investor concerns over the lack of revenue data and future guidance, which could impact confidence in the company's growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CANADIAN NATL RY CO
Apr 23, 2012